Lantheus Holdings, Inc. 8K

Lantheus agreed to an all-cash merger with Curium valued at up to ~$8 billion, including CVRs tied to future product sales milestones, with closing expected in 1H 2027.

Lantheus Holdings, Inc. announced that it has entered into a definitive agreement to be acquired by Curium US Holdings LLC in an all-cash merger under which Lantheus shareholders will receive $102.50 per share in cash at closing plus non-transferable contingent value rights for up to an additional $12.00 per share based on future sales milestones across its global prostate cancer diagnostics, neurology diagnostics, and DEFINITY businesses, implying a total transaction value of up to approximately $8 billion at a premium to recent trading prices, with closing subject to customary shareholder and regulatory approvals and expected in the first half of 2027.

Filing Facts

CIK

1521036

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-329622

Alert Tier

8